13F Holdings
中文EN

BCRX BIOCRYST PHARMACEUTICALS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882796 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.3%
TTM net income YoY-3,996.8%
TTM EPS YoY-2,460.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—

Margins

Gross margin97.9%
Operating margin-30.1%
Net margin-37.4%
FCF margin38.0%
EBITDA margin-29.9%

Returns

ROE—
ROA-69.3%
ROIC (approx.)—
Asset turnover1.85x

Leverage & solvency

Liabilities / assets167.2%
Debt / equity—
Current ratio2.71x
Interest coverage-3.77x

Cash quality & payout

Operating cash flow / net income-1.02x
Accruals ratio-140.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$874.84M$450.71M$331.41M$270.83M$157.17M
Cost of revenue$19.07M$12.27M$4.48M$6.41M$7.23M
Gross profit$855.76M$438.44M$326.93M$264.42M$149.94M
R&D expense$166.13M$174.64M$216.57M$253.30M$208.81M
SG&A expense$348.65M$266.35M$214.07M$159.37M$118.82M
Operating income$340.99M-$2.54M-$103.71M-$148.44M-$177.72M
Interest expense$78.87M$98.52M$108.24M$99.09M$59.29M
Pretax income$267.39M-$86.95M-$226.23M-$244.38M-$181.81M
Income tax$3.53M$1.93M$310,000$2.73M$2.25M
Net income$263.86M-$88.88M-$226.54M-$247.12M-$184.06M
EBITDA$342.38M-$1.30M-$102.05M-$147.00M-$176.94M
EPS (basic)1.26-0.43-1.18-1.33-1.03
EPS (diluted)1.21-0.43-1.18-1.33-1.03
Weighted avg. shares (diluted)218.58M206.70M192.20M185.91M179.12M
Balance sheet
Cash & equivalents$89.74M$106.32M$110.64M$306.24M$504.39M
Short-term investments$185.01M$216.14M$278.34M$119.54M$3.21M
Receivables$106.82M$79.07M$56.95M$50.60M$29.41M
Inventory$5.40M$8.09M$28.68M$27.53M$15.79M
Current assets$404.35M$421.97M$495.97M$516.50M$566.14M
PP&E, net$8.78M$7.78M$7.91M$8.62M$8.71M
Total assets$514.16M$490.42M$516.96M$550.00M$588.15M
Current liabilities$196.07M$160.38M$149.99M$105.51M$103.72M
Long-term debt$0$314.87M$303.23M$231.62M$298.14M
Total debt$0$314.87M$303.23M$231.62M$298.14M
Total liabilities$633.31M$966.35M$972.49M$844.60M$695.14M
Shareholders' equity-$119.15M-$475.93M-$455.53M-$294.60M-$106.99M
Net debt-$89.74M$208.55M$192.59M-$74.61M-$206.25M
Shares outstanding213.06M208.54M205.77M187.91M184.35M
Cash flow statement
Operating cash flow$347.37M-$52.02M-$95.14M-$161.85M-$142.16M
Capital expenditure$2.47M$1.12M$2.17M$1.35M$2.38M
Free cash flow$344.90M-$53.14M-$97.31M-$163.20M-$144.54M
Investing cash flow-$13.69M$52.59M-$131.50M-$128.24M$15.80M
Financing cash flow-$349.93M-$5.76M$32.48M$88.03M$359.67M
Depreciation & amortization$1.39M$1.25M$1.66M$1.44M$777,000
Stock-based compensation$85.07M$65.41M$55.62M$44.70M$34.64M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.